8-KLeadership ChangesShareholder Matters

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jun 27, 2012)

Filed June 27, 2012For Securities:ALNY

Summary

This 8-K filing from Alnylam Pharmaceuticals, Inc. (ALNY) on June 27, 2012, reports on key personnel changes and outcomes from the company's 2012 Annual Meeting of Stockholders. The most significant personnel update is the promotion of Akshay K. Vaishnaw, M.D., Ph.D., to Executive Vice President and Chief Medical Officer, accompanied by an increase in his base salary and incentive compensation target. Additionally, Barry E. Greene, President and Chief Operating Officer, received a base salary increase to enhance competitiveness. The filing also details the results of the Annual Meeting held on June 21, 2012. Stockholders re-elected three Class II directors, approved the company's executive compensation in an advisory vote, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2012. These events provide insights into the company's leadership stability and governance practices.

Key Highlights

  • 1Akshay K. Vaishnaw, M.D., Ph.D. promoted to Executive Vice President and Chief Medical Officer.
  • 2Dr. Vaishnaw's annual base salary increased to $450,000, with his target incentive award percentage raised to 50%.
  • 3Barry E. Greene, President and COO, received a base salary increase to $500,000 to remain competitive.
  • 4Three Class II directors (Dennis A. Ausiello, M.D., John K. Clarke, Marsha H. Fanucci) were re-elected at the Annual Meeting.
  • 5Stockholders approved executive compensation in a non-binding advisory vote.
  • 6PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal year 2012.

Frequently Asked Questions

The primary leadership change is the promotion of Dr. Akshay K. Vaishnaw to Executive Vice President and Chief Medical Officer. His compensation was adjusted accordingly, with an increased base salary and a higher target incentive award. Additionally, the base salary for President and COO Barry E. Greene was increased to ensure competitive compensation.

At the Annual Meeting, stockholders re-elected three Class II directors, provided advisory approval for the compensation of named executive officers, and ratified the appointment of PricewaterhouseCoopers LLP as the company's independent auditor for fiscal year 2012.

Yes, both Dr. Akshay K. Vaishnaw and Mr. Barry E. Greene received base salary increases. Dr. Vaishnaw's salary rose to $450,000, and his annual incentive program target increased from 40% to 50%. Mr. Greene's salary was adjusted to $500,000 to maintain competitiveness within the industry.

The re-election of directors indicates continued confidence from stockholders in the current board's leadership and governance. Ratifying the auditor confirms the company's commitment to financial transparency and compliance with accounting standards, with PricewaterhouseCoopers LLP continuing their role for the fiscal year 2012.